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Abstract
Carbon monoxide (CO) is an endogenously produced gas resulting from the degradation of heme
by heme oxygense or from fatty acid oxidation. Heme oxygenase (HO) enzymes are constitutively
expressed in the kidney (HO-2) and HO-1 is induced in the kidney in response to several
physiological and pathological stimuli. While the beneficial actions of HO in the kidney have been
recognized for some time, the important role of CO in mediating these effects has not been fully
examined. Recent studies using CO inhalation therapy and carbon monoxide releasing molecules
(CORMs) are demonstrating that increases in CO alone can be beneficial to the kidney in several
forms of acute renal injury by limiting oxidative injury, decreasing cell apoptosis, and promoting
cell survival pathways. Renal CO is also emerging as a major regulator of renal vascular and
tubular function acting to protect the renal vasculature against excessive vasoconstriction and to
promote natriuresis by limiting sodium reabsorption in tubule cells. Within this review, recent
studies on the physiological actions of CO in the kidney will be explored as well as the potential
therapeutic avenues that are being developed targeting CO in the kidney which may be beneficial
in diseases such as acute renal failure and hypertension.
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Introduction
Throughout human history, carbon monoxide (CO) has been considered a toxic
environmental gas. Inhalation of as little of 800 parts per million (ppm) can be fatal due to
its binding to hemoglobin which renders it incapable of carrying oxygen. While the toxicity
of environmental CO is widely known, we have only recently begun to appreciate the
important role for endogenously formed CO in regulating physiological processes in organs
such as the kidney. CO is formed in the body from the catabolism of heme by heme
oxygenase (HO) enzymes as well as the oxidation of lipids. It is estimated that the
production rate of CO is 384 μmoles/day in the body with an average CO concentration in
the tissues in the nanomolar range [1]. In the kidney, the primary HO enzymes responsible
for the generation of CO are the constitutively expressed HO-2 isoform and the inducible
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HO-1 isoform. It is difficult to discuss CO and the kidney without mentioning these
important enzymes as manipulation of the levels of the HO proteins has been a major
strategy in altering the levels of CO in the kidney. Although HO enzymes have been greatly
studied in the kidney under normal and pathological conditions, the role of CO in mediating
the response to experimental manipulations of HO protein is not clear. The purpose of this
review is to outline the important role of CO in the regulation of renal function and in
protecting the kidney from injury as well as to highlight areas that may pose new
opportunities for the development of novel therapeutic targets for the treatment of kidney
disease.
CO Signaling in the Kidney
Endogenously produced CO can signal in the cell through multiple pathways as outlined in
Figure 1. One important signaling pathway is the direct binding of CO to metal containing
proteins such as soluble guanylate cyclase (sGC), cytochrome P450 proteins, cytochrome c
oxidase, NADPH oxidase, and nitric oxide synthase [2]. The binding of CO to these proteins
is able to confer a conformational change which can alter their biological activity [3].
Perhaps the most significant signaling pathway for CO in the kidney is the activation of sGC
resulting in the increase in cGMP levels in the kidney. Several studies have demonstrated an
important role for cGMP in the regulation of both vascular and tubular function in the
kidney [4,5,6,7]. A second important signaling pathway for CO is through p38 mitogen-
activated protein kinase (MAPK) pathway which is thought to mediate the cytoprotective,
anti-inflammatory, and anti-apoptotic effects of CO [8,9,10]. Another emerging signaling
pathway for CO is modulation of reactive oxygen species (ROS) formation. CO can either
decrease or increase ROS formation depending on cell compartment where it is acting. For
instance, CO in the cytosol inhibits the activity of NADPH oxidase which lowers superoxide
production in the cell [11,12,13,14,15]. This decrease in superoxide can have several effects
in the kidney including: decreasing sodium reabsorption in the tubules as well as increasing
the bioavailability of nitric oxide to promote vasodilatation of the renal vasculature [16,17].
In contrast, CO in the mitochondria can promote superoxide [11,18]. The increase in
mitochondrial superoxide production results from CO binding to complex IV proteins which
allows for electrons to accumulate in complex III which drives their reaction with oxygen
forming superoxide [19]. This increase in superoxide release from the mitochondria can
induce superoxide dismutases which convert the superoxide to hydrogen peroxide (H2O2)
which can drive further cell signaling [20]. Finally, CO can also signal through other
signaling cascades such as PI3K-Akt, peroxisome proliferator-activated receptor γ (PPAR-
γ), and hypoxia-inducible factor 1 α (HIF-1α) [10,21,22,23].
CO and Kidney Injury
Cisplatin Nephrotoxicity
Cisplatin (CP) is a very effective anti-cancer drug used in the treatment of cancers of the
testis, ovary, head and neck, bladder, lung, cervix and endometrium [24,25,26]. However, its
use is frequently complicated by acute renal injury that often develops as a result of its use
in humans. CP accumulates throughout the nephron with highest concentrations observed in
the S3 segment of the proximal tubule and the thick ascending limb of Henle (TALH).
These two regions of the nephron are also the most susceptible to CP-induced nephrotoxicity
[27]. Despite various hydration protocols devised to minimize nephrotoxicity, 25-35% of
patients experience a significant decline in renal function following CP treatment.
HO-1 induction has previously been demonstrated to limit the extent of CP-induced tubular
cell damage in both in vitro and in vivo models [28,29,30]. Whether the protective effect of
HO-1 induction is due to the actions of CO or bilirubin, is not known. One way to determine
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if increases in CO alone can protect the kidney against CP induced nephrotoxicity is to
increase renal CO levels using carbon monoxide releasing molecules (CORMs). CORMs are
newly developed compounds which have the ability to release CO in vivo [31,32,33,34].
The first generation of CORMs were designed with a metal containing carbonyl group to
which the CO was bound [31,32,33]. The first generation CORMs have several caveats
which one needs to take into account before their use including: 1) the fast release time of
CO at physiological pH which occurs with a half-life between 1-5 minutes, 2) the metal
group of these compounds can result in induction of HO-1 which can lead to further
increases in CO and bilirubin independent of the actions of the CORMs [35], 3) some of
these CORMs are not water soluble and must be delivered in an organic vehicle such as
DMSO. However, a second generation of CORMs has been created in which the CO is
bound to a boron atom instead of a transition metal. These CORMS offer several advantages
of the first generation compounds including 1) slower release of CO with a half-life of 20
min, 2) since these compounds lack a metal groups they do not induce HO-1 in vivo, 3) they
are easily soluble in water. The ability of an intraperitoneal (ip) injection of CORM-A1 to
increase blood carboxyhemoglobin (COHb) levels in mice is summarized in Table 1.
CORM-A1 administration at 7.5 mg/kg resulted in a significant increase in blood COHb
levels for up to 45 min post administration; whereas, administration at 5 mg/kg resulted in a
slight increase in blood COHb levels at 30 minutes following administration.
Our group tested whether increasing CO via treatment with CORMs protects against
cisplatin nephrotoxicity. Mice were treated with either CORM-3, a first generation CORM
(40 mg/kg), or CORM-A1 (5 mg/kg) a second generation CORM prior to exposure to a
single dose of cisplatin (20 mg/kg) and daily for 5 days. Survival rates of 60%, after 3 days
and 25% after 5 days were observed in vehicle treated mice (Figure 2A). Treatment with
CORM-3 or CORM-A1 resulted in an improvement in survival with a 100% and 83%
survival rate after 3 days and a 50% survival rate 5 days after cisplatin (CP) treatment in
each group respectively (Figure 2A). Treatment of mice with the inactive CORMs,
iCORM-3 was associated with a 100% survival rate at 3 days; however, the survival rate
after 5 days was only 29 % (Figure 2A). The increased survival rate in CORM-3 and
CORM-A1 treated mice was associated with a significantly attenuated increase in plasma
creatinine as compared to vehicle and iCORM-3 treated mice (Figure 2B). Our results with
CORM-3 were similar to results of CP nephrotoxicity in the rat [36]. In this study, treatment
of rats with CORM-3 prior to the administration of CP prevented the increase in plasma
creatinine and completely protected the kidney against CP induced tubular apoptosis,
necrosis, cellular desquamation and vacuolization [36]. The anti-apoptotic effects of CO in
CP nephrotoxicity were believed to be mediated via increases in cGMP since blockade with
a sGC inhibitor prevented CORM-3 from attenuating caspase-3 activation in cultured renal
tubular cells [36]. The results of these studies highlight the potential use of CO donors or
CO inhalation therapy to protect the kidney against CP induced nephrotoxicity by limiting
renal tubule cell apoptosis.
Renal Transplantation & Ischemic Renal Failure
There are many factors that contribute to renal allograft rejection including: ischemia-
reperfusion injury and immune rejection of the transplanted kidney. Several studies have
demonstrated a pivotal role for CO in protecting transplanted kidneys from both of these
potential complications. The first line of evidence suggesting the CO may be beneficial to
the kidney during ischemia-reperfusion arose from transplantation studies utilizing CO
inhalation therapy [37,38,39]. In these studies, CO was administered via inhalation for a
little as one hour at a concentration of 250 ppm or continuously at a concentration of 20 ppm
for a period of 30 days following transplantation [37,39]. CO inhalation therapy was
associated with improvements in renal cortical blood flow, creatinine clearance, preservation
Csongradi et al. Page 3
Curr Pharm Biotechnol. Author manuscript; available in PMC 2012 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
of glomerular vascular structures and podocyte viability, decreased tubular cell apoptosis,
and significant lengthening of survival by 2.5 fold as compared to animals breathing
standard room air [39,40]. The protective role for CO in ischemia-reperfusion injury has also
been examined using CORMs as a means of delivering CO. Pretreatment of mice with
CORM-3 one hour before the onset of 40 minutes of renal ischemia-reperfusion resulted in a
significant reduction in the rise in plasma creatinine measured 24 hours after recovery [35].
Interestingly, administration of CORM-3 after the ischemic period did not have the same
effect. CORM-3 administration was also associated with a decrease in renal tubule cell
injury and excretion of neutrophil gelatinase–associated lipocalin (NGAL), a marker of renal
tubule cell injury [35]. Although CORM-3 can induce HO-1, blockade of HO activity with a
specific HO inhibitor did not significantly alter the ability of CORM-3 to lower plasma
creatinine and limit renal injury in this model [35]. All of the protective actions of CORM-3
on renal function and structure occurred without any significant increase in blood COHb
levels which can occur during CO inhalation therapy especially at higher levels of CO [37].
CO has also been demonstrated to modulate the immune response following ischemia-
reperfusion. The hallmarks of the inflammatory response following ischemia-reperfusion
injury are activation of the innate immune system leading to the activation of the adaptive
alloimmune response as well as macrophage infiltration. In a rat transplantation model, CO
inhalation limits both the activation of CD4+ T-cells and alloreactive T-cells and to also
decrease ED1(+) macrophage infiltration [37,41]. CO has also been demonstrated to reduce
the level of inflammatory cytokines such as interferon-γ, interleukin (IL)-6, and tumor
necrosis factor (TNF)-α [37,40]. In addition to its anti-inflammatory properties, CO also has
significant anti-fibrotic actions through inhibition of the extracellular regulated kinase
(ERK)-MAPK and TGF-β pathways [40].
Another area in which CO has been demonstrated to be beneficial is in protection against
cold storage induced injury of the kidney. Cold storage-induced organ injury is a major
determinant of post transplant organ dysfunction. Clinical data has demonstrated that kidney
biopsies of cold stored allografts postreperfusion exhibited greater levels of apoptosis as
compared to allografts obtained from living-related donors suggesting that reperfusion of
cold stored organs may be associated with increased levels of apoptotic cell death [42]. First,
studies in cultured proximal tubule cells demonstrated that treatment with the CO donor,
CORM-3, decreased the amount of apoptosis and lactate dehydrogenase (LDH) release in
cells pretreated before 48 hours of cold storage at 4°C followed by 18 hours of rewarming at
37°C [43]. Similar results were observed when whole kidneys were perfused with a Celsior
solution supplemented with CORM-3 prior to cold storage at 4°C [44]. Kidneys treated with
CORM-3 prior to cold storage displayed higher perfusion flow rate (PFR), glomerular
filtration rate, and reabsorption rates of sodium and glucose as compared to control kidneys
flushed with Celsior solution alone after transplantation [44]. In a separate study,
administration of CORM-3 improved renal blood flow and creatinine clearance when
administered immediately prior to renal implantation after 18 hours of cold storage [45].
While the protective mechanism of CO in cold induced renal failure is not known,
experimental evidence suggest that the protective actions of CO may be mediated through
stimulation of guanylate cyclase, HIF-1 and vascular endothelial growth factor (VEGF)
[23,44].
The experimental evidence demonstrating the protective effects of both CO inhalation
therapy and CORMs in renal ischemia-reperfusion injury associated with transplantation is
strong raising the possibility that CO therapy could be used to protect against ischemia-
reperfusion injury and consequently delayed graft function; however, this data has not
resulted in the widespread adaptation of CO therapy to protect against ischemia reperfusion
injury following transplantation. A recent case report described the successful
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transplantation outcome despite greater than 24 hours of ischemia in a kidney from donor
who succumbed to CO poisoning [46]. Although the blood COHb levels in CO poisoning
victims are clearly too high for clinical use, the potential benefit of CO therapy in renal
transplantation merits further investigation to determine a safe level of CO inhalation can be
achieved in potential organ donors to limit ischemia-reperfusion injury of transplanted
organs.
CO, the Kidney and Blood Pressure Regulation
CO and the Renal Vasculature
The role of CO in the regulation of renal vascular tone is controversial. Several studies using
CO gas, CORMs, HO inducers or HO inhibitors have demonstrated that CO is a vasodilator
of the renal circulation [4,5,47,48]. While the effects of CO in the renal vasculature under
basal conditions may be considered modest, increases in CO are important to protect the
renal vasculature from excessive vasoconstriction due to agents such as angiotensin II,
phenylephrine, and 20-Hydroxyeicosatetrenoic acid (20-HETE) [5,47]. CO has also been
demonstrated to be the major dilatory agent of the renal microcirculation in response to
blockade of nitric oxide (NO) production [49]. CO is believed to result in vasodilatation
ultimately through activation of large conductance calcium-activated potassium (KCa)
channels either directly or as a result of stimulation of sGC resulting in the increase levels of
cGMP (Figure 3A) [4,50,51,52,53]. Renal blood flow remains constant to the kidney despite
fluctuations in blood pressure through autoregulation of renal blood flow. The role of CO in
the renal autoregulatory response is an emerging area. Recent studies have suggested that
induction of HO-1 in the kidney reduces renal autoregulation (decreases constriction of the
afferent arteriole) and that this effect is reversed by inhibition of HO-1 [54]. Interestingly,
the attenuation of renal autogulation can be restored by CO but not biliverdin following HO
inhibition suggesting that CO derived from renal tubular sources may be an important
modulator of afferent arteriolar vasoconstriction in vivo [54,55]. However, because
autoregulation occurs via two distinct mechanisms, myogenic constriction and
tubuloglomerular feedback (TGF), the effect of CO on autoregulation may be due to effects
on TGF via CO acting on renal tubular cells.
Although CO can be an important dilator of the renal circulation, it has also been reported to
act as a vasoconstrictor as well. The vasoconstrictor actions of CO result primarily from the
unusual relationship that it has with NO in the vasculature. Low levels of CO have been
reported to enhance NO production and NO has been reported to induce HO-1 [56,57]. On
the other hand, inhibition of NO stimulates CO production and an increase in CO via
overexpression of HO-1 in vascular smooth muscle cells decreases NO production [58,59].
Recently, it was demonstrated that treatment of rat interlobular arteries with the CO donor,
CORM-3, resulted in vasoconstriction due to increases in cellular superoxide production
[60]. Additional studies in angiotensin II hypertensive mice demonstrated that although
induction of HO-1 lowered blood pressure, it did not normalize and actually resulted in
further impairment of acetylcholine induced NO relaxation [61]. Therefore, it appears that
CO can be both a constrictor and dilator in the renal vasculature depending on the balance
between the levels of HO/CO and NO.
CO and Renal Tubule Function
The first reports of the effect of CO on thick ascending loop of Henle (TALH) function were
performed in isolated, perfused tubules and TALH cells obtained from rats fed a high
potassium diet [62,63]. In these studies, CO was found to stimulate the apical 70-pS K+
channel by patch clamp analysis in isolated TALH cells. Further studies in isolated perfused
TALH tubules demonstrated that incubation with chromium mesoporphyrin (CrMP), an
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inhibitor of HO, resulted in a decrease in sodium and water reabsorption [63]. These studies
would suggest that increases in CO would result in increases in sodium and water
reabsorption in the TALH promoting fluid retention and increases in blood pressure.
However, studies in whole animals have not supported a pro-hypertensive role for HO/CO
in the kidney. First, intravenous administration of the HO inducer, heme, which raised
urinary CO levels, resulted in increase sodium and water excretion [64]. Second, chronic
intrarenal medullary interstitial infusion of CrMP, which decrease renal CO levels as
measured by in vivo microdialysis–oxyhemoglobin CO trapping, resulted in decreased
sodium excretion and increased blood pressure in rats fed normal and high salt diets [65].
Third, direct induction of HO-1 in the renal medulla with cobalt protoporphyrin (CoPP)
significantly attenuated the development of angiotensin II-dependent hypertension in mice
[66]. Last, low level of CO inhalation 60 ppm for 2 hours a day, was demonstrated to reduce
blood pressure in angiotensin II infused low-density lipoprotein (LDL) receptor knockout
mice [67]. The reason for the discrepancy between the results of the initial in vitro studies
and the later in vivo studies is not known but may be due to the differences in approaches (in
vitro vs. in vivo) or the different diets of the animals studies (high potassium versus normal
and high salt).
The major signaling pathway for CO is believed to be mediated by stimulation of sGC
resulting in increased levels of cGMP in the kidney. Both CO production as well as cGMP
levels are increased by elevations in renal perfusion pressure [6,65,68]. Recent studies have
also determined the important role of each of these molecules in mediating increases in
sodium excretion in response to increases in renal perfusion pressure (pressure-natriuresis);
however, the direct link between increased levels of CO and cGMP in the kidney has not
been established. Studies with acute administration of CORMs and chronic induction of
renal HO-1 with hemin in deoxycorticosterone acetate (DOCA)-salt treated rats have
documented increases in urinary and tissue cGMP levels but the effects of chronic increases
in CO alone on cGMP levels in the kidney have not been examined [48,69]. One major
limitation in delineating the relationship between renal cGMP and CO is the ability to
specifically increase renal CO levels chronically without inducing HO-1. CORMs are a
potential solution to the problem; however, they exhibit a very short half-life which makes
chronic infusion problematic [34].
One emerging aspect of CO signaling which may be important to the regulation of sodium
reabsorption in the kidney is its affect on the generation of reactive oxygen species via
cytosolic and mitochondrial sources (Figure 3B) [18]. Studies in immortalized, cultured,
thick ascending loop of Henle (TALH) cells have demonstrated the ability of CO to directly
attenuate angiotensin II-mediated superoxide production [15]. Angiotensin II is known to
increase cellular superoxide production via stimulation of NAD(P)H oxidase [70].
NAD(P)H oxidase mediated increases in superoxide production have also been reported to
increase sodium reabsorption in the thick ascending loop of Henle directly and through
decreases in the bioavailability of NO [71,72]. The effects of CO on angiotensin II-mediated
superoxide production in cultured TALH cells are similar to those observed in primary
cultures of rat TALH cells where overexpression of HO-1 was demonstrated to limit
angiotensin II induced oxidative injury [73]. The decrease in NAD(P)H oxidase mediated
superoxide production in the thick ascending loop of Henle by CO may mediate the anti-
hypertensive actions of HO induction in the kidney in models that exhibit increased levels of
cytosolic superoxide production such as angiotensin II dependent and deoxycorticosterone
acetate (DOCA)-salt hypertension [66,74].
CO may also regulate sodium reabsorption in the kidney via actions on membrane insertion
of transport proteins. For example, recent studies have highlighted an important role for
cGMP in the regulation of apical levels of the Na/K/2Cl co-transporter (NKCC2) in the
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TALH [75,76]. It is hypothesized that increased levels of cGMP result in the increased
turnover of cAMP via activation of cGMP stimulated phosphodiesterase 2 (PDE2) which in
turn decreases the insertion of the NKCC2 channel into the apical membrane, a process that
is regulate by cAMP [77]. Whether CO can sufficiently increase cGMP levels in the TALH
to activate PDE2 and decrease apical NKCC2 levels is not known. In the proximal tubule,
cGMP has also been demonstrated to alter the activity of the Na/Pi cotransporter by
decreasing insertion in the brush-border membrane [78]; however, the ability of CO to
mimic this effect has not been investigated.
CO and the Kidney: Where do we go from here?
As the evidence for the beneficial effects of CO in the kidney accumulates, we are faced
with the daunting task of translating basic experimental findings into clinical application.
Clearly this is a significant challenge as we move into the next decade of research. There are
currently several significant limitations that must be overcome in order to convert what we
have learned about the beneficial actions of CO in the kidney into routine clinical practice.
The first is a paradigm shift from considering CO as a toxic gas when present at high levels
to a potential therapeutic gas when delivered at lower levels. The most intriguing approach
for immediate clinical application would be CO inhalation therapy. One advantage of CO
inhalation therapy is that it could be easily implemented in both clinical and non-clinical
settings. One could imagine patients being treated chronically at home using accurate, dose-
limited inhalation systems. However, much work regarding the appropriate concentration of
CO as well as duration of treatment is needed. The second potential therapeutic avenue of
CO rests in the development of CORMs that could be developed into practical drugs.
Currently, CORMS are limited in the ability to deliver them chronically at therapeutic doses
as well as the ability to have them become specifically activated in vivo. Both of these areas
represent significant hindrances to the development of CORMs as pharmacological tools to
deliver CO to patients in a non-clinical setting.
Much of what we currently know about the affects of CO on the kidney is derived from
studies in which the levels of HO-1 have been altered. Thus, alterations of renal HO levels
offer another potential therapeutic approach to exploiting the therapeutic actions of CO.
However, since HO enzymes also generate metabolites such as free iron and bilirubin,
targeting HO could have additional benefits or create unwanted side-effects depending on
the nature of the specific disease to be treated. CO signaling in the kidney is another area
that can be utilized for the development of potential therapeutics in kidney disease.
Activation of sGC, stimulation of NO production, inhibition of cytostolic superoxide
production, stimulation of PI3K-Akt, are all examples of the pathways that could be targeted
to mimic the action of CO in the kidney to protect the kidney. However, more research is
needed to specifically identify which pathway(s) activated by CO would provide the most
benefit to the kidney in diseases such as acute renal failure, diabetic nephropathy, and
hypertension.
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Figure 1.
Carbon monoxide (CO) signaling in the kidney. Carbon monoxide is mainly generated
through metabolism of heme by heme oxygenase as well as a by-product of lipid
peroxidation. CO mainly signals through activation of soluble guanylate cyclase (sGC)
which increase cellular cGMP levels. CO can also inhibit cystolic NADPH oxidase to limit
superoxide formation (02.) while promoting superoxide formation in mitochondria. CO has
both stimulatory as well as inhibitory actions on nitric oxide (NO) and inhibits inflammation
and apoptosis via activation of mitogen activated protein kinase (MAPK), Phosphoinositide
3-kinase (PI3K)/Atk and peroxisome proliferator-activated receptor γ (PPAR-γ).
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Figure 2.
Effect of carbon monoxide releasing molecules (CORMs), CORM-3, and CORM-A1 on
mortality and plasma creatinine in C57BL/6J mice treated with cisplatin. A) Kaplan–Meier
survival curve of mice after injection of cisplatin (CP) and subsequent treatment with
vehicle, CORM-3, inactive CORM-3 (iCORM-3), and CORM-A1 (n=8). Treatment with
CORM-3 and CORM-A1 increased the survival rate as compared to untrated (CP) and
iCORM-3 treated mice. B) Plasma creatinine levels in mice following CP treatment.
Treatment with CORM-3 and CORM-A1 significantly blunted the increase in plasma
creatinine as compared to CP treated mice, n=8. *= statistically significant P< 0.05 as
compared to CP treated mice.
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Figure 3.
Schematic diagram summarizing the effect of CO on A) the renal vasculature and B) renal
tubules. In the vasculature, CO can cause vasodilatation through increases in cGMP via
stimulation of soluble guanylate cyclase (sGC). The increase in cGMP levels results in
activation of the large conductance calcium activated potassium channel (KCa). Both CO
and NO can also directly activate KCa channels. Low levels of CO also stimulate NO which
leads to activation of KCa via increases in cGMP. However, high levels of CO can inhibit
NO production in the vasculature and cause vasoconstriction. In renal tubules, CO inhibits
superoxide (02.) production to decrease the activity of the sodium-potassium-2 chloride
transporter (NKCC2) in the thick ascending loop of Henle (TALH). Superoxide also
decreases NO levels. NO is an endogenous inhibitor of NKCC2 via cGMP mediated
decreases in apical insertion of the transporter. CO may also have a direct effect on the
NKCC2 transporter to decreases its activity resulting in a decrease in sodium reabsorption in
the TALH.
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